SEQ-400
SEQ-400 is a vaccine against urinary tract infections which is under development for potential medical use. It is a vaccine against the Escherichia coli FimH adhesin protein, which is essential for bacterial infection. The vaccine is being developed by Sequoia Sciences. As of September 2023, it is in phase 2 clinical trials. SEQ-400 is being developed for potential approval and use in the United States.